FDA Grants Expedited Approval to Groundbreaking Pancreatic Cancer Pill Daraxonrasib
The US Food and Drug Administration has given expedited approval to daraxonrasib, a first-of-a-kind pill targeting mutated proteins in over 90% of pancreatic cancer cases.
- FDA approved daraxonrasib under expedited review.
- The pill targets a mutated protein driving over 90% of pancreatic cancer cases.
Sources
- France 24 — FDA approves new drug Rasonque to treat advanced pancreatic cancer
- Semafor — FDA approves breakthrough drug for pancreatic cancer treatment
- BBC — US drug agency approves breakthrough treatment for pancreatic cancer
- The Hill — FDA approves groundbreaking new pancreatic cancer drug
- The Guardian — FDA gives expedited approval to new groundbreaking pancreatic cancer drug
- Hacker News — FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
- STAT News — STAT+: FDA approves new pancreatic cancer drug expected to usher in new era of treatment